Longitudinal Phonatory Characteristics After Botulinum Toxin Type A Injection

1996 ◽  
Vol 39 (5) ◽  
pp. 968-980 ◽  
Author(s):  
Kimberly V. Fisher ◽  
Ronald C. Scherer ◽  
Chwen G. Guo ◽  
Ann S. Owen
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Spasmodic Dysphonia ◽  
Adductor Spasmodic Dysphonia ◽  
Wide Range ◽  
Glottal Flow ◽  
Vocal Quality ◽  
The Voice

Following Botulinum Toxin Type A injection, glottal competency of an adductor spasmodic dysphonia patient is thought to vary over a wide range. This study quantifies variability in laryngeal adduction for one such patient over a 10-week period. Analyses of kinematic and aerodynamic measures were used to track the voice weekly. The measures included the electroglottographic waveform width (EGGW50), nondimensional electroglottographic slope quotient (SLQ), glottal flow open quotient (FOQ), dc glottal flow, and nondimensional glottal flow peak quotient (FPQ). The results suggested that change in degree of glottal adduction over time can be observed even when vocal instability is present within each recording session. Perceptual ratings of vocal quality (breathy to pressed) were related to the laryngeal measures. The coefficient of variation for EGGW50 and the percentage of dichrotic phonations reached minima during sessions with predominantly breathy and hypoadducted phonation. The methods used in this study show potential to aid decisions about dose level and sources of perceptual adductor spasmodic dysphonia symptoms for a given patient.

Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study

2017 ◽  
Vol 31 (3) ◽  
pp. 378.e19-378.e24 ◽  
Author(s):  
Wonjae Cha ◽  
Jeon Yeob Jang ◽  
Soo-Geun Wang ◽  
Ji-Heon Kang ◽  
Min-Gyu Jo
Keyword(s):  
Botulinum Toxin ◽  
Pilot Study ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Spasmodic Dysphonia ◽  
Prospective Pilot Study ◽  
Adductor Spasmodic Dysphonia ◽  
Liquid Type

Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population

2014 ◽  
Vol 128 (7) ◽  
pp. 649-653 ◽  
Author(s):  
N K Nerurkar ◽  
T P Banu
Keyword(s):  
Botulinum Toxin ◽  
Indian Population ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Dose Titration ◽  
Optimum Dose ◽  
Spasmodic Dysphonia ◽  
International Studies ◽  
Adductor Spasmodic Dysphonia

AbstractObjectives:This study aimed to evaluate the demographics of spasmodic dysphonia in the Indian population and to analyse the optimum dose titration of botulinum toxin type A in this group. A comparative analysis with international studies was also performed.Method:The study involved a retrospective analysis and audit of botulinum toxin type A dose titration in spasmodic dysphonia patients who visited our voice clinic between January 2005 and January 2012.Results:The average total therapeutic dose required for patients with adductor spasmodic dysphonia was 4.2 U per patient per vocal fold (total 8.4 U per patient), and for patients with abductor spasmodic dysphonia, it was 4.6 U per patient.Conclusion:Our audit revealed that 80 per cent of the spasmodic dysphonia patients were male, which contrasts dramatically with international studies, wherein around 80 per cent of spasmodic dysphonia patients were female. Our study also revealed a higher dose titration of botulinum toxin for the Indian spasmodic dysphonia population in both adductor and abductor spasmodic dysphonia cases.

Effects of Botulinum Toxin Type A Injections on Aerodynamic Measures of Spasmodic Dysphonia

1996 ◽  
Vol 106 (3) ◽  
pp. 296-300 ◽  
Author(s):  
Scott G. Adams ◽  
Lisa C. Durkin ◽  
Jonathan C. Irish ◽  
David L.H. Wong ◽  
Elizabeth J. Hunt
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Spasmodic Dysphonia

Alternating Unilateral Botulinum Toxin Type A (BOTOX®) Injections for Spasmodic Dysphonia

1996 ◽  
Vol 106 (12) ◽  
pp. 1476-1481 ◽  
Author(s):  
Michael J. Koriwchak ◽  
James L. Netterville ◽  
Todd Snowden ◽  
Mark Courey ◽  
Robert H. Ossoff
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Spasmodic Dysphonia

scholarly journals Anatomic Considerations in Botulinum Toxin Type A Therapy for Spasmodic Dysphonia

1994 ◽  
Vol 104 (6) ◽  
pp. 656???662 ◽  
Author(s):  
Paul F. Castellanos ◽  
George A. Gates ◽  
Gregory Esselman ◽  
Felix Song ◽  
Michael W. Vannier ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Spasmodic Dysphonia

Botox Treatment in Adductor Spasmodic Dysphonia

2002 ◽  
Vol 45 (3) ◽  
pp. 469-481 ◽  
Author(s):  
Frank Boutsen ◽  
Michael P. Cannito ◽  
Merlin Taylor ◽  
Brenda Bender
Keyword(s):  
Botulinum Toxin ◽  
Significant Variation ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Spasmodic Dysphonia ◽  
Treatment Benefit ◽  
Treatment Conditions ◽  
Adductor Spasmodic Dysphonia ◽  
Efficacy Research ◽  
Botulinum Toxin Treatment

Over the years many studies have been conducted to document the treatment effects of Botulinum toxin type A in adductor spasmodic dysphonia. The results of these studies have led to the view that overall Botulinum toxin treatment is moderately effective. This study reviews efficacy research qualitatively and quantitatively to determine the extent to which this conclusion is fully supported by the data. Although the data indicate moderate overall improvement as a result of Botulinum toxin treatment, they also suggest significant variation across patients, measurements, and treatment conditions. This result, together with methodological limitations and lack of standardization in BT efficacy research, justifies caution when making inferences regarding BT treatment benefit in adductor spasmodic dysphonia.

Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia

2007 ◽  
Vol 122 (1) ◽  
pp. 52-56 ◽  
Author(s):  
P Casserly ◽  
C Timon
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Treatment Success ◽  
Botulinum Toxin Type ◽  
Prognostic Indicator ◽  
Spasmodic Dysphonia ◽  
Toxin A ◽  
Motor Processing ◽  
Adductor Spasmodic Dysphonia

AbstractSpasmodic dysphonia is a disabling voice condition caused by a chronic neurological disorder of central motor processing. Present therapy is directed at relief of symptoms rather than cure. Botulinum toxin type A injection into the thyroarytenoid muscle has become the pre-eminent approach for treatment of adductor spasmodic dysphonia. Botulinum toxin A injections can be performed in an out-patient setting under electromyographic guidance. We present our experience with 153 injections in 14 patients with adductor spasmodic dysphonia over a 10-year period. We demonstrate that the electromyography signal is a reliable prognostic indicator in terms of efficacy, and that patients' subjective opinion is a valid indicator of treatment success and future treatment strategy.

Sign in / Sign up

Export Citation Format

Share Document